Compare ImmunityBio Inc. Common Stock (IBRX) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ImmunityBio Inc. Common Stock vs Natera Inc. Common Stock — how do they compare? ImmunityBio Inc. Common Stock trades at $9.99 (market cap $10.39B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 5.5× ImmunityBio Inc. Common Stock's market cap, and ImmunityBio Inc. Common Stock is more actively traded (11,509,049 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 6 Days and Natera Inc. Common Stock for 0 Days on average.
| IBRX | NTRA | |
|---|---|---|
Market Cap | $10.39B | $57.03B |
Volume | 11,509,049 | 1,131,157 |
Sector | Health | Health |
52-Week High | $11.55 | $425.64 |
52-Week Low | $1.98 | $179.42 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $10.84B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ImmunityBio (IBRX) trades at $9.80, down 3.16% on the day, amid a bullish technical setup and strong analyst support. The company reported revenue growth to $166 million in 2026 but remains deeply unprofitable with a net loss of $992 million. Recent FDA approval expansion for ANKTIVA in bladder cancer and high-profile executive appointments signal operational momentum, though cash burn remains a concern with negative operating cash flow.
Outlook is cautiously optimistic given the unanimous buy ratings and regulatory milestones, but investment carries high risk due to persistent losses, heavy reliance on financing, and competitive pressures. The stock's trajectory hinges on successful commercialization and pipeline execution to achieve profitability.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
